海角破解版

IBMX

cAMP pathway activator; Inhibits cyclic nucleotide phosphodiesterases

IBMX

cAMP pathway activator; Inhibits cyclic nucleotide phosphodiesterases

Catalog #
(Select a product)
cAMP pathway activator; Inhibits cyclic nucleotide phosphodiesterases
Request Pricing Request Pricing

Overview

IBMX is an inhibitor of cyclic nucleotide phosphodiesterases (PDEs; IC鈧呪個 = 19, 50, 18, 13, 32, 7, and 50 碌M for PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, and PDE11, respectively). By inhibiting PDEs, IBMX increases cellular cAMP and cGMP levels, activating cyclic-nucleotide-regulated protein kinases.

DIFFERENTIATION
路 Used in combination with fibroblast growth factor (FGF) 1, dopamine, 12-O-tetradecanoylphorbol-13-acetate (TPA), and forskolin to induce expression of the dopaminergic neuron marker tyrosine hydroxylase in neurons derived from the human NT2 cell line (Iacovitti et al.).
路 Used in combination with dexamethasone, insulin, and indomethacin for in vitro induction of adipogenic differentiation of unrestricted somatic stem cells (USSCs), a CD45-negative population of stem cells isolated from human cord blood (K枚gler et al.; Pittenger et al.).
路 Induces neural differentiation from human umbilical cord blood-derived mesenchymal stem cells (MSCs; Tio et al.).
路 Promotes the differentiation of rat neural progenitor cells (NPCs) into functional neurons in vitro (Lepski et al.).
Cell Type
Adipocytes, Mesenchymal Stem and Progenitor Cells, Neural Stem and Progenitor Cells, Neurons
Species
Human, Mouse, Non-Human Primate, Other, Rat
Application
Differentiation
Area of Interest
Neuroscience, Stem Cell Biology
CAS Number
28822-58-4
Chemical Formula
颁鈧佲个贬鈧佲倓狈鈧凮鈧
Purity
鈮 98%
Pathway
cAMP
Target
PDE

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
72764, 72762
Lot #
All
Language
English
Document Type
Product Name
Catalog #
72764, 72762
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (9)

Targeting TRPM3 as a potential therapeutic approach for autosomal dominant polycystic kidney disease H. G眉l and J. Davies Scientific Reports 2025 Feb

Abstract

Cystic diseases, especially autosomal dominant polycystic kidney disease (ADPKD; incidence approx. 1/1000), are a leading cause of renal failure, caused by appearance and growth of renal cysts that can lead to renal failure in middle age. Most ADPKD cases are caused by mutations in PKD1 or PKD2, encoding polycystin-1 (PC1) and polycystin-2 (PC2). PC1 is a mechanosensor that controls PC2, a Ca2+-permeable cation channel that, by regulating cytoplasmic Ca2+, prevents adenylyl cyclase producing cyst-promoting concentrations of cAMP. In other systems, there is evidence that PC2 interacts with TRPM3. We therefore examined the effect of pharmacological activators and inhibitors of TRPM3 on cyst formation in cultured mouse kidney rudiments exposed to a range of concentrations of forskolin, a cAMP-elevating drug commonly used experimentally to induce cysts in cultured kidneys. We found that TRPM3 inhibitors (isosakuranetin, primidone, diclofenac) increased cyst formation, while TRPM3 activators (CIM0216 and nifedipine) greatly reduced cyst formation and reduced the sensitivity of kidneys to forskolin. These preclinical, in-vitro data suggest that TRPM3 may be a promising target in ADPKD management.
Derivation and long-term maintenance of porcine skeletal muscle progenitor cells S. Dan-Jumbo et al. Scientific Reports 2024 Apr

Abstract

Culture of muscle cells from livestock species has typically involved laborious enzyme-based approaches that yield heterogeneous populations with limited proliferative and myogenic differentiation capacity, thus limiting their use in physiologically-meaningful studies. This study reports the use of a simple explant culture technique to derive progenitor cell populations from porcine muscle that could be maintained and differentiated long-term in culture. Fragments of semitendinosus muscle from 4 to 8 week-old piglets (n = 4) were seeded on matrigel coated culture dishes to stimulate migration of muscle-derived progenitor cells (MDPCs). Cell outgrowths appeared within a few days and were serially passaged and characterised using RT-qPCR, immunostaining and flow cytometry. MDPCs had an initial mean doubling time of 1.4 days which increased to 2.5 days by passage 14. MDPC populations displayed steady levels of the lineage-specific markers, PAX7 and MYOD, up until at least passage 2 (positive immunostaining in about 40% cells for each gene), after which the expression of myogenic markers decreased gradually. Remarkably, MDPCs were able to readily generate myotubes in culture up until passage 8. Moreover, a decrease in myogenic capacity during serial passaging was concomitant with a gradual increase in the expression of the pre-adipocyte markers, CD105 and PDGFRA, and an increase in the ability of MDPCs to differentiate into adipocytes. In conclusion, explant culture provided a simple and efficient method to harvest enriched myogenic progenitors from pig skeletal muscle which could be maintained long-term and differentiated in vitro, thus providing a suitable system for studies on porcine muscle biology and applications in the expanding field of cultured meat.
cAMP promotes the differentiation of neural progenitor cells in vitro via modulation of voltage-gated calcium channels. Lepski G et al. Frontiers in cellular neuroscience 2013 JAN

Abstract

The molecular mechanisms underlying the differentiation of neural progenitor cells (NPCs) remain poorly understood. In this study we investigated the role of Ca(2+) and cAMP (cyclic adenosine monophosphate) in the differentiation of NPCs extracted from the subventricular zone of E14.5 rat embryos. Patch clamp recordings revealed that increasing cAMP-signaling with Forskolin or IBMX (3-isobutyl-1-methylxantine) significantly facilitated neuronal functional maturation. A continuous application of IBMX to the differentiation medium substantially increased the functional expression of voltage-gated Na(+) and K(+) channels, as well as neuronal firing frequency. Furthermore, we observed an increase in the frequency of spontaneous synaptic currents and in the amplitude of evoked glutamatergic and GABAergic synaptic currents. The most prominent acute effect of applying IBMX was an increase in L-type Ca(2+)currents. Conversely, blocking L-type channels strongly inhibited dendritic outgrowth and synapse formation even in the presence of IBMX, indicating that voltage-gated Ca(2+) influx plays a major role in neuronal differentiation. Finally, we found that nifedipine completely blocks IBMX-induced CREB phosphorylation (cAMP-response-element-binding protein), indicating that the activity of this important transcription factor equally depends on both enhanced cAMP and voltage-gated Ca(2+)-signaling. Taken together, these data indicate that the up-regulation of voltage-gated L-type Ca(2+)-channels and early electrical excitability are critical steps in the cAMP-dependent differentiation of SVZ-derived NPCs into functional neurons. To our knowledge, this is the first demonstration of the acute effects of cAMP on voltage-gated Ca(+2)channels in NPC-derived developing neurons.